2. Immunology/Inflammation
  3. PD-1/PD-L1
  4. Durvalumab (anti-PD-L1)

Durvalumab (anti-PD-L1)  (Synonyms: MEDI 4736 (anti-PD-L1))

Cat. No.: HY-P9919A Pureza: 99.0%
COA
SDS
Technical Support

Durvalumab (anti-PD-L1)(MEDI 4736) is a human anti-PD-L1 protein monoclonal antibody. Durvalumab (anti-PD-L1) completely blocks PD-L1 binding to PD-1 and CD80, IC 50 are 0.1 and 0.04 nM respectively, has anti-tumor activity.

Para uso exclusivo en investigación. No vendemos a pacientes.

No. CAS : 1428935-60-7

Tamaño Precio Stock Cantidad
Muestra gratis (100 μg)   Solicite ahora  
1 mg En stock
5 mg En stock
10 mg   Obtener un presupuesto  
50 mg   Obtener un presupuesto  

* Seleccione Cantidad antes de agregar artículos.

This product is a controlled substance and not for sale in your territory.

Revisión del cliente

Based on 6 publication(s) in Google Scholar

Other Forms of Durvalumab (anti-PD-L1):

Durvalumab (anti-PD-L1) Related Antibodies

Top Publications Citing Use of Products

    Durvalumab (anti-PD-L1) purchased from MedChemExpress. Usage Cited in: Preprints. 10 May 2022.

    Migration-focused results of ECIS tests on T98G and U87 glioblastoma cells treated with Radiation and Durvalumab. Representative plot of normalized resistance in the first 40 hours posttreatment for T98G.

    Durvalumab (anti-PD-L1) purchased from MedChemExpress. Usage Cited in: Preprints. 10 May 2022.

    Barrier function-focused results of ECIS tests on T98G glioblastoma cells treated with radiation and durvalumab. Representative plot of the barrier function Rb posttreatment for T98G shown.

    Durvalumab (anti-PD-L1) purchased from MedChemExpress. Usage Cited in: Cancer Discov. 2020 Dec;10(12):1872-1893.  [Abstract]

    4T1-hPD-L, where the basal mouse PD-L1 was knocked out followed by adding back human PD-L1 gene, and 4T1-hB7-H4 cells were orthotopically injected into the left fourth mammary fat pad and allow to grow around 100 mm3, followed by injection of Cam (25 mg/kg, i.p.) for 4 times, NGI-1 nanoparticle (10 mg/kg, i.v.) as well as PD-L1 antibody Durvalumab (5 mg/kg, i.p.) for 3 times. The tumor growth was monitored twice per week. n=8 mice per group.

    Durvalumab (anti-PD-L1) purchased from MedChemExpress. Usage Cited in: Cancer Discov. 2020 Dec;10(12):1872-1893.  [Abstract]

    Survival curve of the mice of the combination of Cam, NGI-1 nanoparticle and Durvalumab (5 mg/kg, i.p., 3 times). n=8 mice per group.

    Durvalumab (anti-PD-L1) purchased from MedChemExpress. Usage Cited in: Cancer Discov. 2020 Dec;10(12):1872-1893.  [Abstract]

    4T1-hPD-L, where the basal mouse PD-L1 was knocked out followed by adding back human PD-L1 gene, and 4T1-hB7-H4 cells were orthotopically injected into the left fourth mammary fat pad and allow to grow around 100 mm3, followed by injection of Cam (25 mg/kg, i.p.) for 4 times, NGI-1 nanoparticle (10 mg/kg, i.v.) as well as PD-L1 antibody Durvalumab (5 mg/kg, i.p.) for 3 times. Tumor tissues were subjected to the immunohistochemically staining with anti-CD8 antibody.

    • Actividad biológica

    • Pureza y Documentación

    • Referencias

    • Revisión del cliente

    Descripciòn

    Durvalumab (anti-PD-L1)(MEDI 4736) is a human anti-PD-L1 protein monoclonal antibody. Durvalumab (anti-PD-L1) completely blocks PD-L1 binding to PD-1 and CD80, IC 50 are 0.1 and 0.04 nM respectively, has anti-tumor activity[1][2].

    Isotype

    Human IgG1 kappa
    Recommend Isotype Controls
    Species Reactivity

    Human
    IC50 & Target

    B7-H1/PD-L1/CD274
    In Vitro

    Durvalumab (0.02-20 μg/mL, 3 days) overcomes the inhibitory effect of PD-L1 on T cell activation[1].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Durvalumab (anti-PD-L1) Related Antibodies
    In Vivo

    Durvalumab (0.1-5 mg/kg, intraperitoneal injection, twice a week, three weeks) suppresses human tumor growth in mouse models through T cell inhibition[1].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: HPAC/A375 xenograft mouse model[1]
    Dosage: 0.01, 0.1, 1, 5 mg/kg; twice a week; three weeks
    Administration: Intraperitoneal injection (i.p.)
    Result: Inhibited tumor growth of HPAC, A375 and had no effect on tumor xenografts in the absence of T cells.
    Gene ID

    29126  [NCBI]

    Accession
    Application

    ELISA, FACS, Functional assay
    Conjugated

    Unconjugated
    Reconsititution

    The product can be reconstituted/diluted with sterile PBS or saline.
    Peso molecular

    146.32 kDa

    No. CAS
    Appearance

    Liquid

    Color

    Colorless to light yellow

    SMILES

    [Durvalumab (anti-PD-L1)]
    Envío

    Shipping with dry ice.
    Formulation

    Please refer to the lot-specific COA for specific buffer information.
    Almacenamiento

    Please store the product under the recommended conditions in the Certificate of Analysis.
    Format
    • Human IgG1 kappa
    Biological Activity
    • Flow cytometry analysis of PD-L1 overexpression CHO cells labelling PD-L1 with Durvalumab at 20 nM (Red). Goat anti human IgG Fc (Alexa Fluor488) was used as the secondary antibody at 1/1000 dilution. Isotype control - human IgG (Blue). Unlabeled control - Unlabelled cells (Gray).
    Pureza y Documentación
    Referencias
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Durvalumab (anti-PD-L1) Related Classifications

    • Calculadora de molaridad

    • Calculadora de dilución

    The molarity calculator equation

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass   Concentration   Volume   Molecular Weight *
    = × ×

    The dilution calculator equation

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
    × = ×
    C1   V1   C2   V2
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Durvalumab (anti-PD-L1)1428935-60-7MEDI 4736 (anti-PD-L1)PD-1/PD-L1PD-1/Programmed death-ligand 1Monoclonal antibodiesanti-tumorInhibitorinhibitorinhibit

    Productos vistos recientemente:

    Consulta en línea

    Your information is safe with us. * Required Fields.

    Nombre del producto

    		  

    Requested Quantity *

    Nombre del solicitante *

    		 

    Saludo

    Direcciòn del E-mail *

    		 

    Número de teléfono *

    Department

    		 

    Nombre de la Organizaciòn *

    City

    Provincia

    Country or Region *

    		      

    Observaciones

    Consulta para venta a granel

    Inquiry Information

    Nombre del producto:
    Durvalumab (anti-PD-L1)
    Cat. No.:
    HY-P9919A
    Cantidad:
    MCE Japan Authorized Agent:

    Revisión del cliente

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Nombre del producto

    		  

    Lot #

    Nombre del solicitante *

    		 

    Direcciòn del E-mail *

    Número de teléfono

    		 

    Department *

    Nombre de la Organizaciòn *

    		 

    Country or Region *

    Observaciones

    SAFETY DATA SHEET (SDS)

    English - EN (251 KB) Français - FR (251 KB) Deutsch - DE (251 KB) Norwegian - NO (251 KB) Español - ES (251 KB) Swedish - SV (251 KB) Italian - IT (251 KB) Korean - KR (251 KB) Portuguese - PT (251 KB)

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.